Spectral Diagnostics (Canada) acquires septic shock rights:
This article was originally published in Clinica
Executive Summary
Spectral Diagnostics (Canada) has acquired patent-pending technology for early septic shock detection. The royalty- bearing deal also includes a collaborative research agreement with the Toronto Hospital team that developed the test. Spectral intends to develop a point-of-care test for critical care unit use. Septic shock affects around 400,000 North Americans every year. Treatment costs $5-10,000 million in the US alone.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.